Crossbow Therapeutics
1 known investors
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
AI & Machine LearningBiotechMedical Devices
Investors · 1
In the news
- Pharma Funding Roundup: Excalipoint Therapeutics Completes $68.7 Million Seed Finance Round, Crossbow Therapeutics Raises $77 Million in Series B Financing | PharmExecpharmexec.com · 2026
- Crossbow Therapeutics raises funds for cancer trialbioxconomy.com · 2026
- Crossbow raises $77M for new cancer immunotherapies | BioPharma Divebiopharmadive.com · 2026
- Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancerbusinesswire.com · 2026
- Crossbow Therapeutics Raises $80M in Series A Financingfinsmes.com · 2023
- Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancerglobenewswire.com · 2023